Aurixim is under clinical development by BioIntegrator and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Aurixim’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aurixim overview
Aurixim is under development for the treatment of B-cell Non-Hodgkin lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, small lymphocytic lymphoma, lymphoma of lien marginal zone cells. The drug candidate is an infusion, which is administered through intravenous route. It is a rituximab conjugate and acts by targeting CD20.
BioIntegrator overview
BioIntegrator, a subsidiary of ChemRar High-Tech Center, is focused on the development and production of drugs based on recombinant proteins and small molecules for the treatment of autoimmune and oncological diseases. BioIntegrator is headquartered in Moscow, Russia.
For a complete picture of Aurixim’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
